Developer docs
API playgroundTry for free, no card

Search company profiles

Aptorum Group

Full company profile

uuid0003str

Namestring
Aptorum Group
Legal namestring
Aptorum Group Limited
Company typeenum
Public
Founded yearint
2017
Descriptiontext

Aptorum Group Limited (Nasdaq: APM; Euronext Paris: APM) is a clinical-stage biopharmaceutical company founded in 2017 by Ian Huen and headquartered in London, with operational offices in New York, Singapore, Hong Kong, and Mississauga. The company develops therapeutic assets targeting unmet medical needs in oncology (including orphan oncology indications), infectious diseases, and autoimmune disorders, supported by two proprietary drug-discovery platforms: the Smart-Act series, which systematically screens existing approved molecules for new indications, and the Acticule series, focused on oncology and infectious disease therapeutics. Aptorum also co-developed a molecular-based rapid pathogen identification and detection diagnostics technology with Accelerate Technologies Pte Ltd, the commercialization arm of Singapore's Agency for Science, Technology and Research (A*STAR).

Aptorum's business model is primarily pre-revenue: therapeutic development relies on future one-time licensing or commercialization economics, and the company has historically funded operations through equity offerings (e.g., a $3M registered direct offering in January 2025, up to $6M in October 2025) and a $3M convertible note subscribed by Aenco Technologies Limited in December 2022. In July 2025, Aptorum entered a definitive all-stock merger with DiamiR Biosciences Corp. — approved by shareholders in June 2026 and expected to close before fiscal 2027 — which would add recurring diagnostic-services revenue through DiamiR's CLIA-certified, CAP-accredited laboratory, including an APOE testing platform validated in partnership with Instant NanoBiosensors and published microRNA biomarker signatures for glioblastoma detection. Post-merger headquarters is planned for Princeton, New Jersey.

Following the merger, Aptorum would target healthcare providers, clinical laboratories, and pharmaceutical partners across North America, Europe, and East/Southeast Asia. Customer concentration is presently undefined given the absence of commercial revenue; the company employs between 11 and 50 staff and has experienced recurring operating losses. As of March 2026, the company was under a Nasdaq minimum bid price deficiency notice with sub-$1 trading and a 180-day compliance grace period expiring September 1, 2026.

Short descriptiontext

Aptorum Group is a clinical-stage biopharmaceutical company developing therapeutic assets in oncology, infectious disease, and autoimmune disorders via its Smart-Act and Acticule platforms, and, through a pending merger with DiamiR Biosciences, blood-based diagnostics for glioblastoma and Alzheimer's disease.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersLondon, United Kingdom
HQ citystring
London
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices5 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
clinical-stage biopharmaceutical, oncology therapeutics development, infectious disease drug discovery, drug repurposing platforms, molecular diagnostic testing
Industry4 codes
PRIMARYHLAAAIAK
In Vivo Discovery & Translational Models Platforms (humanized models, PK/PD, efficacy)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAALAN
Laboratory Developed Tests (LDTs) & Specialized Clinical Lab Assays
SECONDARYHLAHAOAI
Molecular POCT / NAAT Systems (PCR/Isothermal platforms & cartridges)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Point-of-Care Testing (POCT) & Rapid Diagnostics
SECONDARYHLAGAEAG
Bioanalytical & PK/PD Sample Analysis (Trial Support)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)
NAICS code4 codes
  • Pharmaceutical and Medicine Manufacturing3254
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Medical and Diagnostic Laboratories6215
SIC code3 codes
  • Pharmaceutical Preparations2834
  • Services-Medical Laboratories8071
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
Clinical-stage biopharmaceutical and diagnostics
No data
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Therapeutic asset commercialization
TypeOne Time License
Description

Pre-revenue clinical-stage biopharmaceutical company developing therapeutic assets in oncology, autoimmune, and infectious diseases. Revenue expected upon successful clinical development and regulatory approval.

businesswire.com
2Diagnostic services
TypeSubscription Recurring
Description

Following merger with DiamiR Biosciences, Aptorum will generate revenue from clinical laboratory diagnostic services including APOE testing for Alzheimer's disease and microRNA-based tests for glioblastoma, operated through DiamiR's CLIA-certified, CAP-accredited laboratory.

genomeweb.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Aptorum Group is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. Its pipeline is enriched by drug discovery platforms enabling systematic screening of approved drug molecules, a microbiome-based research platform for metabolic diseases, and a co-developed molecular rapid pathogen identification and detection diagnostics technology. Following the pending merger with DiamiR Biosciences, Aptorum will also offer blood-based diagnostic tests for brain health conditions including Alzheimer's disease and glioblastoma.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Non-invasive blood plasma test for glioblastoma detection using microRNA signatures published in peer-reviewed journal Diagnostics
+1 more record
Product overview1 text field

Aptorum Group is a clinical-stage biopharmaceutical company with a diversified product portfolio comprising two drug development series (Smart-Act Series and Acticule Series) focused on therapeutic assets in oncology and infectious diseases, along with a proprietary molecular rapid pathogen identification and detection diagnostics technology developed in partnership with Accelerate Technologies Pte Ltd. The company also operates drug discovery platforms enabling systematic screening of existing approved drug molecules and microbiome-based research for metabolic diseases.

Product and service1 record
1Smart-Act Series
Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
1New York University (NYU)
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2025-11-19
Description

DiamiR Biosciences and Aptorum Group collaboration with NYU for microRNA biomarker research for neurodegeneration, with findings presented at CTAD 2025 Conference. Research funded by NIH grants.

globenewswire.com
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2025-11-19
Description

DiamiR Biosciences and Aptorum Group collaboration with University of Pennsylvania for microRNA biomarker research for neurodegeneration, with findings presented at CTAD 2025 Conference. Research funded by NIH grants.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-07-16
Description

Aptorum Group announced a definitive all-stock merger agreement with DiamiR Biosciences, with DiamiR becoming a wholly-owned subsidiary. The merger was approved by shareholders of both companies on June 9-10, 2026 and is expected to close before fiscal 2027. The combined entity will focus on blood-based tests for brain health and other diseases, headquartered in Princeton, New Jersey. DiamiR brings CLIA-certified, CAP-accredited clinical laboratory capabilities and proprietary microRNA biomarker technology.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Co-development of novel molecular-based rapid pathogen identification and detection diagnostics technology with Accelerate Technologies Pte Ltd, the commercialization arm of Singapore's Agency for Science, Technology and Research (A*STAR).

5Covar Pharmaceuticals
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Development site in Canada operated in partnership with Covar Pharmaceuticals for drug development activities.

aptorumgroup.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Catalyst Pharmaceuticals (CPRX) is explicitly cited as the primary peer comparator in Aptorum's revenue analysis. Both are small-cap clinical-stage biopharmaceutical companies with oncology/orphan disease focus, providing a direct benchmark for Aptorum's scale and pipeline economics.

TypeDirect peer
Description

DiamiR is Aptorum's announced merger target and will become a wholly-owned subsidiary. Both companies share the microRNA biomarker platform focus and overlap directly on blood-based diagnostics for brain health (glioblastoma and Alzheimer's), making them direct operating peers in the combined entity.

TypeDirect peer
Description

C2N Diagnostics is a clinical-stage diagnostics company developing blood-based biomarker tests for Alzheimer's disease, including PrecivityAD. Directly comparable to Aptorum/DiamiR's planned APOE testing platform for Alzheimer's, serving the same neurology providers and patient population.

TypeDirect peer
Description

Quanterix (QTRX) develops ultra-sensitive biomarker detection platforms including microRNA-based assays used in neurology and oncology research. Directly comparable on the underlying microRNA detection technology and blood-based neurology biomarker applications that Aptorum/DiamiR are pursuing.

TypeDirect peer
Description

Algernon Pharmaceuticals is a small clinical-stage biopharmaceutical company focused on drug repurposing for CNS and other indications. Closely comparable to Aptorum's Smart-Act drug discovery platform that systematically screens existing approved drug molecules for new therapeutic applications.

TypeDirect peer
Description

Aprea Therapeutics (APRE) is a clinical-stage oncology biopharmaceutical company with a similar small-cap profile. Comparable to Aptorum in therapeutic area focus (oncology), pipeline maturity (early-stage clinical assets), and capital-raising pattern typical of small public biotechs.

7Cassava Sciences
TypeEmerging player
Description

Cassava Sciences (SAVA) is a clinical-stage biopharmaceutical focused on Alzheimer's disease therapeutics and diagnostics. Comparable on the brain health/neurology focus that overlaps with the DiamiR-merged Aptorum diagnostics franchise and the broader neurology indication strategy.

8Diffusion Pharmaceuticals
TypeDirect peer
Description

Diffusion Pharmaceuticals (DFFN) is a small clinical-stage biopharmaceutical with similar scale, public listing dynamics, and pipeline profile. Provides a comparable benchmark for Aptorum's market capitalization, liquidity profile, and small-cap public biotech economics.

TypeBroad incumbent
Description

Bio-Techne (TECH) is an established life sciences tools and diagnostics company that provides reagents and platforms for biomarker research including microRNA detection. Comparable as a broader incumbent in the diagnostic tools and reagents space that Aptorum/DiamiR will compete within for neurology biomarker applications.

TypeEmerging player
Description

Prothena (PRTA) is a clinical-stage biotechnology company developing therapies for neurodegenerative diseases including Alzheimer's. Comparable to Aptorum's therapeutic development ambitions in neurology and infectious disease, with a more advanced pipeline but similar disease-area focus.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Aptorum Group

Clinical-stage biopharmaceutical and diagnosticsaptorumgroup.com

Aptorum Group is a clinical-stage biopharmaceutical company developing therapeutic assets in oncology, infectious disease, and autoimmune disorders via its Smart-Act and Acticule platforms, and, through a pending merger with DiamiR Biosciences, blood-based diagnostics for glioblastoma and Alzheimer's disease.

What Aptorum Group does

Aptorum Group Limited (Nasdaq: APM; Euronext Paris: APM) is a clinical-stage biopharmaceutical company founded in 2017 by Ian Huen and headquartered in London, with operational offices in New York, Singapore, Hong Kong, and Mississauga. The company develops therapeutic assets targeting unmet medical needs in oncology (including orphan oncology indications), infectious diseases, and autoimmune disorders, supported by two proprietary drug-discovery platforms: the Smart-Act series, which systematically screens existing approved molecules for new indications, and the Acticule series, focused on oncology and infectious disease therapeutics. Aptorum also co-developed a molecular-based rapid pathogen identification and detection diagnostics technology with Accelerate Technologies Pte Ltd, the commercialization arm of Singapore's Agency for Science, Technology and Research (A*STAR).

Aptorum's business model is primarily pre-revenue: therapeutic development relies on future one-time licensing or commercialization economics, and the company has historically funded operations through equity offerings (e.g., a $3M registered direct offering in January 2025, up to $6M in October 2025) and a $3M convertible note subscribed by Aenco Technologies Limited in December 2022. In July 2025, Aptorum entered a definitive all-stock merger with DiamiR Biosciences Corp. — approved by shareholders in June 2026 and expected to close before fiscal 2027 — which would add recurring diagnostic-services revenue through DiamiR's CLIA-certified, CAP-accredited laboratory, including an APOE testing platform validated in partnership with Instant NanoBiosensors and published microRNA biomarker signatures for glioblastoma detection. Post-merger headquarters is planned for Princeton, New Jersey.

Following the merger, Aptorum would target healthcare providers, clinical laboratories, and pharmaceutical partners across North America, Europe, and East/Southeast Asia. Customer concentration is presently undefined given the absence of commercial revenue; the company employs between 11 and 50 staff and has experienced recurring operating losses. As of March 2026, the company was under a Nasdaq minimum bid price deficiency notice with sub-$1 trading and a 180-day compliance grace period expiring September 1, 2026.

Aptorum Group firmographics

Firmographics
Name
Aptorum Group
Legal name
Aptorum Group Limited
Website
https://aptorumgroup.com
Company type
Public
Founded year
2017
Operating status
Operating
Headcount range
1–10 employees
Short description
Aptorum Group is a clinical-stage biopharmaceutical company developing therapeutic assets in oncology, infectious disease, and autoimmune disorders via its Smart-Act and Acticule platforms, and, through a pending merger with DiamiR Biosciences, blood-based diagnostics for glioblastoma and Alzheimer's disease.
Ownership category
akta.pro rank

Aptorum Group industry classification

Industry
Product category
Clinical-stage biopharmaceutical and diagnostics
NAICS
Pharmaceutical and Medicine Manufacturing (3254), Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Medical and Diagnostic Laboratories (6215)
SIC
Pharmaceutical Preparations (2834), Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLAAAIAK
In Vivo Discovery & Translational Models Platforms (humanized models, PK/PD, efficacy)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAALAN
Laboratory Developed Tests (LDTs) & Specialized Clinical Lab Assays
SECONDARYHLAHAOAI
Molecular POCT / NAAT Systems (PCR/Isothermal platforms & cartridges)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Point-of-Care Testing (POCT) & Rapid Diagnostics
SECONDARYHLAGAEAG
Bioanalytical & PK/PD Sample Analysis (Trial Support)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)

Keywords

  • Clinical-stage biopharmaceutical
  • Oncology therapeutics development
  • Infectious disease drug discovery
  • Drug repurposing platforms
  • Molecular diagnostic testing

Where Aptorum Group is headquartered

Location

Headquarters

HQ city
London
HQ country
United Kingdom
HQ region
Europe

Offices5 records

Markets served

Aptorum Group business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Therapeutic asset commercialization: Pre-revenue clinical-stage biopharmaceutical company developing therapeutic assets in oncology, autoimmune, and infectious diseases. Revenue expected upon successful clinical development and regulatory approval.
  2. Diagnostic services: Following merger with DiamiR Biosciences, Aptorum will generate revenue from clinical laboratory diagnostic services including APOE testing for Alzheimer's disease and microRNA-based tests for glioblastoma, operated through DiamiR's CLIA-certified, CAP-accredited laboratory.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels3 records

Aptorum Group product offering

Product offering

Core offering

Aptorum Group is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. Its pipeline is enriched by drug discovery platforms enabling systematic screening of approved drug molecules, a microbiome-based research platform for metabolic diseases, and a co-developed molecular rapid pathogen identification and detection diagnostics technology. Following the pending merger with DiamiR Biosciences, Aptorum will also offer blood-based diagnostic tests for brain health conditions including Alzheimer's disease and glioblastoma.

Product overview

Aptorum Group is a clinical-stage biopharmaceutical company with a diversified product portfolio comprising two drug development series (Smart-Act Series and Acticule Series) focused on therapeutic assets in oncology and infectious diseases, along with a proprietary molecular rapid pathogen identification and detection diagnostics technology developed in partnership with Accelerate Technologies Pte Ltd. The company also operates drug discovery platforms enabling systematic screening of existing approved drug molecules and microbiome-based research for metabolic diseases.

Differentiator

Problem solved

Functional benefit

Products and services

  • Smart-Act Series

Quantifiable outcome

  • Non-invasive blood plasma test for glioblastoma detection using microRNA signatures published in peer-reviewed journal Diagnostics
  • +1 more outcomes

Companies that use Aptorum Group

Customer profile

Segments4 records

Ideal customer profiles2 records

Aptorum Group technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Aptorum Group partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered minor and core.

  • New York University (NYU)minorStrategic or Co-development Partner · 19 November 2025DiamiR Biosciences and Aptorum Group collaboration with NYU for microRNA biomarker research for neurodegeneration, with findings presented at CTAD 2025 Conference. Research funded by NIH grants.
  • University of PennsylvaniaminorStrategic or Co-development Partner · 19 November 2025DiamiR Biosciences and Aptorum Group collaboration with University of Pennsylvania for microRNA biomarker research for neurodegeneration, with findings presented at CTAD 2025 Conference. Research funded by NIH grants.
  • DiamiR Biosciences CorpcoreStrategic or Co-development Partner · 16 July 2025Aptorum Group announced a definitive all-stock merger agreement with DiamiR Biosciences, with DiamiR becoming a wholly-owned subsidiary. The merger was approved by shareholders of both companies on June 9-10, 2026 and is expected to close before fiscal 2027. The combined entity will focus on blood-based tests for brain health and other diseases, headquartered in Princeton, New Jersey. DiamiR brings CLIA-certified, CAP-accredited clinical laboratory capabilities and proprietary microRNA biomarker technology.
  • Accelerate Technologies Pte LtdcoreStrategic or Co-development PartnerCo-development of novel molecular-based rapid pathogen identification and detection diagnostics technology with Accelerate Technologies Pte Ltd, the commercialization arm of Singapore's Agency for Science, Technology and Research (A*STAR).
  • Covar PharmaceuticalsminorStrategic or Co-development PartnerDevelopment site in Canada operated in partnership with Covar Pharmaceuticals for drug development activities.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Aptorum Group competitors and assessment

Company assessment

Direct peers

  • Catalyst Pharmaceuticals: Catalyst Pharmaceuticals (CPRX) is explicitly cited as the primary peer comparator in Aptorum's revenue analysis. Both are small-cap clinical-stage biopharmaceutical companies with oncology/orphan disease focus, providing a direct benchmark for Aptorum's scale and pipeline economics.
  • DiamiR Biosciences: DiamiR is Aptorum's announced merger target and will become a wholly-owned subsidiary. Both companies share the microRNA biomarker platform focus and overlap directly on blood-based diagnostics for brain health (glioblastoma and Alzheimer's), making them direct operating peers in the combined entity.
  • C2N Diagnostics: C2N Diagnostics is a clinical-stage diagnostics company developing blood-based biomarker tests for Alzheimer's disease, including PrecivityAD. Directly comparable to Aptorum/DiamiR's planned APOE testing platform for Alzheimer's, serving the same neurology providers and patient population.
  • Quanterix: Quanterix (QTRX) develops ultra-sensitive biomarker detection platforms including microRNA-based assays used in neurology and oncology research. Directly comparable on the underlying microRNA detection technology and blood-based neurology biomarker applications that Aptorum/DiamiR are pursuing.
  • Algernon Pharmaceuticals: Algernon Pharmaceuticals is a small clinical-stage biopharmaceutical company focused on drug repurposing for CNS and other indications. Closely comparable to Aptorum's Smart-Act drug discovery platform that systematically screens existing approved drug molecules for new therapeutic applications.
  • Aprea Therapeutics: Aprea Therapeutics (APRE) is a clinical-stage oncology biopharmaceutical company with a similar small-cap profile. Comparable to Aptorum in therapeutic area focus (oncology), pipeline maturity (early-stage clinical assets), and capital-raising pattern typical of small public biotechs.
  • Diffusion Pharmaceuticals: Diffusion Pharmaceuticals (DFFN) is a small clinical-stage biopharmaceutical with similar scale, public listing dynamics, and pipeline profile. Provides a comparable benchmark for Aptorum's market capitalization, liquidity profile, and small-cap public biotech economics.

Emerging players

  • Cassava Sciences: Cassava Sciences (SAVA) is a clinical-stage biopharmaceutical focused on Alzheimer's disease therapeutics and diagnostics. Comparable on the brain health/neurology focus that overlaps with the DiamiR-merged Aptorum diagnostics franchise and the broader neurology indication strategy.
  • Prothena Corporation: Prothena (PRTA) is a clinical-stage biotechnology company developing therapies for neurodegenerative diseases including Alzheimer's. Comparable to Aptorum's therapeutic development ambitions in neurology and infectious disease, with a more advanced pipeline but similar disease-area focus.

Broad incumbents

  • Bio-Techne: Bio-Techne (TECH) is an established life sciences tools and diagnostics company that provides reagents and platforms for biomarker research including microRNA detection. Comparable as a broader incumbent in the diagnostic tools and reagents space that Aptorum/DiamiR will compete within for neurology biomarker applications.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Aptorum Group financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Aptorum Group leadership team

Management profile

Number of profiles

Profiles8 records

Aptorum Group subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Aptorum Group funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Aptorum Group M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Aptorum Group

What does Aptorum Group do?

Aptorum Group is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. Its pipeline is enriched by drug discovery platforms enabling systematic screening of approved drug molecules, a microbiome-based research platform for metabolic diseases, and a co-developed molecular rapid pathogen identification and detection diagnostics technology. Following the pending merger with DiamiR Biosciences, Aptorum will also offer blood-based diagnostic tests for brain health conditions including Alzheimer's disease and glioblastoma.

Is Aptorum Group a public or private company?

Aptorum Group is a public company. It is classified as public and is currently operating.

When was Aptorum Group founded?

Aptorum Group was founded in 2017. It employs 1 to 10 people.

Where is Aptorum Group based?

Aptorum Group is headquartered in London, United Kingdom, in the Europe region.

How does Aptorum Group make money?

Two revenue lines are on record. Therapeutic asset commercialization is the primary driver. The others are diagnostic services.

Who are Aptorum Group's main competitors?

Direct peers on record are Catalyst Pharmaceuticals, DiamiR Biosciences, C2N Diagnostics, Quanterix, Algernon Pharmaceuticals, Aprea Therapeutics and Diffusion Pharmaceuticals. Emerging players are Cassava Sciences and Prothena Corporation. Bio-Techne is listed as a broad incumbent.

Does Aptorum Group have an API?

No public API is recorded for Aptorum Group.

What industry is Aptorum Group in?

Aptorum Group's product category is Clinical-stage biopharmaceutical and diagnostics. Its primary akta.pro industry code is HLAAAIAK, In Vivo Discovery & Translational Models Platforms (humanized models, PK/PD, efficacy), with a secondary code of HLAAALAN, Laboratory Developed Tests (LDTs) & Specialized Clinical Lab Assays. Its NAICS code is 3254 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
MarketScreenerAptorum to Implement 1-for-10 Reverse Stock SplitAptorum Group Limited announced plans to implement a 1-for-10 reverse stock split of its shares. This corporate action reduces the number of outstanding shares while proportionally increasing the share price, a measure often used to meet minimum share price requirements for continued exchange listing. The company is a United Kingdom-based clinical-stage biopharmaceutical firm focused on oncology and infectious disease therapeutics.SahmcapitalAptorum Group Announces 1-For-10 Reverse Stock Split, Effective July 20; Proposed Merger With DiamiR Biosciences Anticipated To Close Around July 20Aptorum Group has announced a 1-for-10 reverse stock split effective July 20, 2026, approved by shareholders on June 9, 2026, to increase the per-share trading price for Nasdaq compliance. The company's proposed merger with DiamiR Biosciences is anticipated to close on or around July 20, 2026, following which Aptorum will redomicile as a Delaware corporation under the new name Niki BioSolutions, Inc. and trade under the symbol "NIKI" on the Nasdaq Capital Market on a split-adjusted basis.FinancialContent Business PageAptorum Group Provides Update on DiamiR Biosciences MergerAptorum Group announced the anticipated closing of its all-stock merger with DiamiR Biosciences Corp. on or about July 20, 2026, following shareholder approval on June 9, 2026. In connection with the merger, Aptorum will implement a 1-for-10 reverse stock split and redomicile from the Cayman Islands to Delaware, with the combined entity renamed Niki BioSolutions, Inc. trading on Nasdaq Capital Market under the ticker "NIKI." The reverse split is intended to increase the per-share trading price to maintain compliance with Nasdaq's minimum bid price requirement for continued listing.Stock TitanAptorum Merger Expected July 20; 1-for-10 SplitAptorum Group announced the anticipated closing of its all-stock merger with DiamiR Biosciences on or about July 20, 2026, following shareholder approval on June 9, 2026. The post-merger company will be renamed Niki BioSolutions, Inc. and trade on Nasdaq under the ticker "NIKI" with a new CUSIP number, after implementing a 1-for-10 reverse share split to meet Nasdaq's minimum bid price requirement for continued listing. As part of the transaction, Aptorum will redomicile from the Cayman Islands to Delaware, with DiamiR becoming a wholly-owned subsidiary of the combined entity.GlobeNewswireAptorum Group Announces Collaboration between DiamiR Biosciences and AlzLabs Precision Diagnostics for Alzheimer’s Disease BiomarkersAptorum Group, DiamiR Biosciences, and AlzLabs Precision Diagnostics announced a collaboration to generate blood-based biomarker data for Alzheimer's disease, including p-Tau 217, amyloid 42/40, and neurofilament light. The companies are also proceeding with an all-stock merger, with shareholders approving it on June 9, 2026, and expecting closure before fiscal 2027.Investing.comAptorum shareholders approve merger with DiamiR Biosciences By Investing.comAptorum Group Limited shareholders voted to approve an all-stock merger with DiamiR Biosciences Corp at a meeting on Monday, with DiamiR shareholders also granting approval on the same day. The transaction will result in DiamiR becoming a wholly owned subsidiary of Aptorum upon completion. The companies expect the merger to close before fiscal 2027, subject to customary closing conditions.Investing.comAptorum shareholders approve merger with DiamiR Biosciences By Investing.comAptorum Group Limited shareholders voted to approve an all-stock merger with DiamiR Biosciences Corp, with DiamiR shareholders also approving the transaction on the same day. Upon completion, DiamiR will become a wholly owned subsidiary of Aptorum, and the companies expect the deal to close before fiscal 2027, subject to customary closing conditions. Separately, the companies announced the publication of a study in the journal Diagnostics on a blood plasma test for glioblastoma using specific microRNA signatures as non-invasive biomarkers.GlobeNewswireAptorum Group Announces Shareholder Approval of Proposed Merger with DiamiR BiosciencesAptorum Group Limited announced that its shareholders voted on June 9, 2026 to approve an all-stock merger transaction with DiamiR Biosciences Corp, with DiamiR's shareholders also approving the deal the same day. The combined transaction, which was originally announced in July 2025, will make DiamiR a wholly owned subsidiary of Aptorum Group and remains subject to customary closing conditions with an expected close before fiscal 2027. The companies stated that the combined entity will be positioned to accelerate commercialization efforts and expand strategic partnerships in the life sciences sector.Stock TitanAptorum Group Announces Shareholder Approval of Proposed Merger with DiamiR BiosciencesAptorum Group announced on June 10, 2026, that its shareholders voted to approve the proposed all-stock merger with DiamiR Biosciences Corp, with DiamiR's shareholders also voting in favor on the same day. Under the deal terms, DiamiR will become a wholly owned subsidiary of Aptorum Group, combining two healthcare companies focused on biopharmaceuticals and diagnostic solutions respectively. The transaction, first announced in July 2025, remains subject to customary closing conditions and is expected to close before fiscal 2027.Defense WorldHead-To-Head Survey: Aptorum Group (NASDAQ:APM) versus Catalyst Pharmaceuticals (NASDAQ:CPRX)This article presents a comparative analysis of Aptorum Group (NASDAQ:APM) and Catalyst Pharmaceuticals (NASDAQ:CPRX) across multiple investment metrics including earnings, profitability, analyst ratings, valuation, and institutional ownership. Catalyst Pharmaceuticals outperformed Aptorum Group on 11 of 13 factors evaluated, with higher revenue ($588.99 million vs. $430,000), positive net income ($214.33 million), and stronger institutional ownership (79.2% vs. 3.8%). Analysts favor Catalyst Pharmaceuticals with a consensus price target of $34.00 implying 31.53% upside potential.